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ABSTRACT OF DISSERTATION

EFFECTS OF CHROMIUM ON MOUSE SPLENIC T LYMPHOCYTES
AND
EFFECTS OF ETHANOL EXPOSURE DURING EARLY
NEURODEVELOPMENT ON BEHAVIORS IN MICE
The dissertation consists of three major projects with the focus on the
immunotoxicity of chromium and the behavior disorders caused by early ETOH
exposure respectively
Hexavalent chromium [Cr(VI)] is widely used in various industrial processes and
has been recognized as a carcinogen. As the first line of host defense system, the
immune system can be a primary target of Cr(VI). T cell population represents a
major arm of the immune system that plays a critical role in host anti-tumor
immunity. Dysfunction of T cells compromises host anti-tumor immunity resulting
in oncogenesis. Using mouse splenic T cells as an in vitro model system, the present
study assessed the effects of Cr(VI) on T cell functions, as the first step of our
investigation of the mechanism underlying Cr(VI)-inhibited immunosurveillance and
carcinogenesis. Our results showed that Cr(VI) decreased the viability of CD4+ and
CD8+ T cells, inhibited T cell activation, functions, including cytokine release, and
degranulation.
Fetal ethanol (ETOH) exposure can damage the developing central nervous system
and lead to cognitive and behavioral deficits, known as fetal alcohol spectrum
disorders (FASD). The use of animal models, especially mouse models is essential
for investigating the neurogenetic mechanism of fetal ETOH effects and screening
pharmacotherapies against it, due to the extensive knowledge of mouse genetics.
However, the availability of mouse model is limited. Via adopting various dosage,
timing and administration routes of ETOH exposure, we developed two mouse
models to assess behavioral or cognitive changes caused by fetal ETOH exposure in
pre-weaning and adolescent period. Our results show that high dosage of ETOH
exposure (4 g/kg) during PD 4-10 resulted in hyperactivity, disinhibition, and deficits
in learning and memory in mouse offspring, which lays the groundwork for the future

FASD research.
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Chapter 1: Effects of hexavalent chromium on mouse splenic T
lymphocytes

Synopsis
Background: Hexavalent chromium [Cr(VI)] is widely used in various industrial
processes and has been recognized as a carcinogen. As the first line of host defense
system, the immune system can be a primary target of Cr(VI). T cell population
represents a major arm of the immune system that plays a critical role in host
anti-tumor immunity. Dysfunction of T cells, such as exhaustion under the persistent
presence of tumor antigen, compromise host anti-tumor immunity resulting in
oncogenesis. Previous studies have shown Cr(VI) exposure alters the phenotype of
human peripheral blood lymphocytes. However, the mechanism of the alteration and
whether such an alteration in immunity affects immunosurveillance and promotes
carcinogenicity are not clear.
Methods: Mouse splenic T cells were used in the present study as an in vitro model
system. With the treatment of 2 or 5 µM Cr(VI), the viability, activation,
proliferation, and function of splenic T cells were assessed in vitro.
Results: Cr(VI) decreased the viability of CD4+ and CD8+ T cells, inhibited T cell
functions, including activation, cytokine release, and degranulation.
Conclusion: The data obtained from the current in vitro study set up a foundation for
our further investigation of the mechanism underlying Cr(VI)-inhibited
immunosurveillance and carcinogenesis.

1

Keywords
Cr(VI), T cell, immune response, toxicity, cancer

2

Introduction
Chromium(Cr) exists widely in nature and is used in various industrial processes
(Barceloux, 1999). Humans can be exposed to chromium through inhalation,
ingestion, or dermal exposure (Shrivastava et al., 2002). In spite of 6 valence states
of chromium, only Cr(III) and Cr(VI) are of biological significance with respect to
their toxicity and carcinogenicity (Steinhagen et al., 2004). Cr(VI) is considered as a
human carcinogen and chronic exposure to Cr(VI) is associated with an increased
incidence of various cancers (Costa, 1997, Salnikow and Zhitkovich, 2008).
The immune system is an interactive network of lymphoid organs, cells, humoral
factors, and cytokines, which together act as the first line of host defense system
against infection or cancer (Parkin and Cohen, 2001, Candeias and Gaipl, 2016,
Subramanian et al., 2015). The immune system monitors the host body, recognizing
and eliminating newly arising cancer cells to stop/control tumor formation in a
process termed ‘immunosurveillance’. Cancer cells possess tumor antigens. The
encounter between cancer cells and immune system initiates a process known as
‘immunoediting’ that can bring about three outcomes: elimination, equilibrium or
escape of cancer cells from immunosurveillance. Hence, the host immunity
suppresses tumor development, whereas tumor formation implicates a successful
escape of tumor cells from host immunosurveillance. Previous studies have shown
that Cr(VI) may impair the immune system (Dangleben et al., 2013, Akbar et al.,
2011, Salsano et al., 2004) and occupational exposure to Cr(VI) decreased the
number of lymphocytes in peripheral blood of chromate workers (Tanigawa et al.,
3

1995, Qian et al., 2013). However, the effects of Cr(VI) on host anti-tumor immunity
is not clear.
The host anti-tumor immunity can be carried out in a form of cell-mediated
immunity. As an important component of cell-mediated immunity, T cells play a
critical role in immunosurveillance (Vorhees and Williams, 2006). CD4+ and CD8+
are two major T cell subpopulations. Quiescent naïve T cells mainly reside in
secondary lymphoid organs such as the spleen (Mebius and Kraal, 2005). Upon
attacked by either exogenous or endogenous insult, T cells are activated and undergo
rapidly clonal expansion (proliferation). Activated CD4+ T cells perform their
effector functions through secreting cytokines, whereas activated CD8+ T cells
mediate lysis of target cells via releasing perforin and granules (Broere(1) et al.,
2011). Due to its high content of T cells, the culture of mouse splenocytes has been
widely used as an in vitro model system to test immunotoxicity to T cells by a
variety of insults (Song et al., 2014, Pestka et al., 1994).
Our goal is to understand the effects of Cr(VI) on host anti-tumor immunity and its
contribution to Cr(VI) carcinogenicity. As the first step, in the current study, we
aimed to determine whether Cr(VI) at environmentally relevant concentrations
affects the viability, activation, proliferation and effector function of T cells. Using
mouse splenic T cell culture as an in vitro model, our results showed that Cr(VI)
decreased the viability of CD4+ and CD8+ T cells, inhibited the activation,
proliferation, cytokine secretion and cytotoxic function of the splenic T cells. These
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results set up a foundation for our further investigation of the mechanism underlying
Cr(VI)-induced immunosurveillance inhibition and carcinogenesis.

Materials and Methods

Animals
Male and female C57BL/6 mice (8-week-old) were purchased from Harlan
Laboratory (Indianapolis, IN) and maintained under specific pathogen-free
conditions at the Division of Laboratory Animal Resources, University of Kentucky
Medical Center (Lexington, KY). All protocols were in accordance with NIH
guidelines and approved by the Institutional Animal Care and Use Committee of the
University of Kentucky.

Chemicals
Potassium dichromate (K2Cr2O7) was obtained from Sigma-Aldrich (St. Louis, MO)
and used for Cr(VI) treatment. RPMI-1640 medium and fetal bovine serum (FBS)
were purchased from Gibco (Grand Island, NY). Anti-CD3/CD28, APC-conjugated
anti-CD4, PE-conjugated anti-CD4, PE-Cy5.5-conjugated anti-CD4,
APC-conjugated anti-CD8, FITC-conjugated anti-CD8, PE-conjugated anti-69,
FITC-conjugated anti-CD25, FTIC-conjugated CD107a were from BioLegend (San
Diego, CA). Mouse IL-2, IL-4, IL-10 ELISA MAXTM Deluxe Set and
carboxyfluorescein diacetate succinimidyl ester (CFSE) cell division tracker kit were
obtained from BioLegend (San Diego, CA).
5

Splenocytes cultures
C57BL/6 mice were sacrificed and their spleens were aseptically removed. A
suspension of splenocytes was obtained by mesh desegregation with a cell strainer
(Corning Incorporated, Durham, NC). Erythrocytes were lysed in RBC lysis buffer
(10X) (BioLegend, San Diego, CA), and the cell pellets were washed with
RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine,
100 IU/mL of penicillin and streptomycin, and 0.1%β- mercaptoethanol. The cell
number was assessed by exclusion of trypan blue (Sigma-Aldrich, St. Louis, MO).
Cells were plated at a density of 6×106 cells/ml and maintained in a humidified
atmosphere of 5% CO2 at 37℃.

Cell viability assay
T cell viability was determined via propidium iodide (PI) staining assay. PI is
impermeable to intact plasma membranes of living cells, allowing the accurate
determination of cell viability in a variety of studies (Yeh et al., 1981, Bank, 1987).
In this experiment, the isolated splenocytes were plated on 24-well plates (Costar,
Washington) containing 1 ml of RPMI-1640 complete medium. Then cells were
treated with 0, 2 or 5 µM Cr(VI). Three independent experiments were conducted
and each treatment contained triplicates. After 24 hours, cells were washed and
re-suspended in 0.5 ml FACS buffer (PBS, 2% FBS and 0.1% sodium azide). Single
cell suspensions were labeled with APC-conjugated anti-CD4 and FITC-conjugated
anti-CD8 antibodies on ice for 30 mins in the dark. Shortly before flow cytometric
6

analysis, 20 µl of the PI solution was added to 0.5 ml of cell suspension. Then, cells
were analyzed with BD FACS Calibur flow cytometry (San Jose, California).

T cell activation assay
Anti-CD3 and anti-CD28 antibodies were used to induce T cell activation (Frauwirth
and Thompson, 2002) which can be detected by the increase of CD69 and CD25
levels on T cell surface (Morzadec et al., 2012). Briefly, splenocytes were treated
with anti-CD3 and CD28 antibodies (1 µg/ml) for 24 hours. Cells were stained with
APC-conjugated anti-CD4, anti-CD8, PE-conjugated anti-CD69 and
FITC-conjugated anti-CD25 antibodies. After 30 mins staining, cells were analyzed
using BD FACSCalibur flow cytometry. PI staining was used to exclude dead cells.

T cell proliferation assay
The proliferation of splenic T cells was measured as previously described (Quah and
Parish, 2010). Briefly, the intracellular fluorescent dye, CFSE, covalently labels
intracellular molecules. With each cell division, these fluorescent molecules are
equally distributed in daughter cells, shown as the half-reduced CFSE intensity in
daughter cells, which allows T cells proliferation to be examined by flow cytometry
(Quah and Parish, 2010). Therefore, the splenocytes were labeled with CFSE and
cultured in a 24-well plate in medium with or without anti-CD3/CD28 antibodies (1
µg/ml). Cells were then treated with 0, 2 or 5 µM Cr (VI) for 96 hours and stained
with PE-Cy5.5 conjugated anti-CD4 and APC-conjugated anti-CD8 antibodies, and
cell proliferation was analyzed by flow cytometry. PI staining was used to exclude
7

dead cells.

Determination of cytokine levels
The cytokine levels were determined using ELISA kits as described previously
(Katial et al., 1998). Splenocytes were cultured in 24-well plates and treated with
either anti-CD3/CD28 antibodies alone or anti-CD3/CD28 antibodies plus Cr (VI) (2
or 5 µM) for 24 hours. Cell-free supernatants were collected for measurement of
cytokine levels by ELISA.

Detection of the cytolytic function of CD8+ T cells
As previously described, CD8+ T cell-mediated cytotoxicity was evaluated via
measuring the levels of CD107a which is expressed on T cell surface following
activation-induced degranulation (Betts et al., 2003). Briefly, 1 ×106 cells were
cultured in complete RPMI and treated with 2 or 5 µM Cr(VI). After 18 hours,
anti-CD3/CD28, FTIC conjugated CD-107a or hamster IgG isotype control
antibodies were added. One hour later, 1 µl monensin solution (1000×) was added to
each well. Cells were then cultured in a humidified atmosphere of 5% CO2 at 37℃
for additional 5 hours and then were stained with APC-conjugated CD8 antibodies.
The expression of CD107a on T cell surface was detected by flow cytometry. Three
independent experiments were conducted with triplicates for each treatment group.

Statistical analysis
All experiments were repeated at least three times with triplicates each. Data were
expressed as mean ± standard deviation. GraphPad Prism was used to analyze all
8

data. Comparison of more than two groups was made with a one-way analysis of
variance (ANOVA) followed by Tukey’s test. A p value < 0.05 was considered
significant.

Results

Cr(VI) decreases T cell viability
We first determined the effects of Cr(VI) on the viability of CD4+ and CD8+ T cells.
The splenocytes were treated with 2 or 5 µM Cr(VI) in vitro and their viability was
determined by PI staining followed by flow cytometry. Lymphocytes were first
identified by a low forward scatter (FSC) and low side scatter (SSC) gate. Live
CD4+ and CD8+ T cells were then defined based on their cell markers and PI staining.
The viability of CD4+ and CD8+ T cells was calculated based on the percentage of
live CD4+ or CD8+ T cells among total splenocytes as relevance to controls (Figure
1.1). Cr(VI) decreased the viability of CD4+ cells, which reached the significant
level at 5 µM, but not at 2 µM (Figure 1.1A and B), whereas the viability of CD8+ T
cells was significantly decreased by Cr(VI) at both 2 and 5 µM (Figure 1.1C and D).

9

Figure 1.1.Cr(VI) decreases T cell viability.
(A ) and (C) show the percentages of live CD4+ and CD8+ among total splenocytes
after the splenocytes were treated with 2 or 5 µM Cr(VI) for 24 hours. (B) and (D)
show the viability of CD4+ and CD8+, which was calculated by dividing the
percentage of live CD4+ and CD8+ in total splenocytes of each treatment group by
10

that of the control group. Three independent experiments were conducted and each
treatment group contained three replicates. Data were shown as mean ± SEM. *: P <
0.05 vs controls.

Cr(VI) inhibits T cell activation
To determine the effect of Cr(VI) on T cell activation, splenocytes were treated with
2 or 5 µM Cr(VI) plus anti-CD3/anti-CD28 antibodies in vitro and the expression of
CD69 and CD25 on the surface of CD4+ and CD8+ T cells were measured by flow
cytometry. CD4 and CD8 populations were identified via CD4 and CD8 markers
within live lymphocytes gate, respectively. The percentage of activated T cells
(CD69+ or CD25+) among total T cells was derived from their percentages within
live lymphocytes, shown as in Figure 1.2. Compared to isotype control and
non-stimulation group, anti-CD3/anti-CD28 antibodies treatment significantly
activated the T cells, as evidenced by the increase of CD69+ or CD25+ T cells.
Co-treatment of 2 or 5 µM Cr(VI) significantly decreased CD69+ T cells among total
T cells (Figure 1.2A and B), while CD25+ T cells were significantly decreased by 5
µM but not 2 µM Cr(VI) treatment (Figure 1.2C and D).

11
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Figure 1.2. Cr(VI) inhibits T cell activation.
(A) and (C) show the percentage of CD69+ and CD25+ T cells within live
lymphocyte gate after they were treated with 2 or 5 µM Cr(VI) plus anti-CD3 and
anti-CD28 antibodies for 24 hours. (B) and (D) show the percentages of CD69+ or
CD25+ T cells among total live T cells, which were calculated by dividing the
percentage of CD69+or CD25+ T cells within live lymphocyte by total T in that gate.
Three independent experiments were conducted with triplicates for each treatment
13

group. Data were shown as mean ± SEM. *: P < 0.05 as compared with
aCD3/aCD28 treatment group.

Cr(VI) inhibits T cell proliferation
Following activation, T cells undergo rapid proliferation. We then determined T cell
proliferation by CFSE assay. Mouse splenocytes were pre-stained with CFSE and
then treated with 2 or 5 µM Cr(VI) plus anti-CD3/anti-CD28 before flow cytometry
analysis. The proliferation of CD4 or CD8 T cells was determined by the percentage
of divided CD4+ and CD8+ T cells among total live CD4+ and CD8+ T cells,
respectively, as shown in Figure 1.3. Cr(VI) significantly decreased the proliferation
of CD4+ T cells at both 2 and 5 µM (Figure 1.3A and B), while the proliferation of
CD8+ T cells was only significantly inhibited by 5 µM Cr(VI), but not 2 µM (Figure
1.3C and D).

14
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Figure 1.3. Cr(VI) inhibits T cell proliferation.
After the splenocytes were treated with 2 or 5 µM Cr(VI) plus anti-CD3 and
anti-CD28 antibodies for 96 hours, the percentages of divided CD4+ among all live
CD4+ cells (A) and the percentages of divided CD8+ among all live CD8+ cells (C)
were marked with M1. The percentages of proliferative CD4+ and CD8+ cells were
shown in (B) and (D). Four independent experiments were conducted with triplicates
for each treatment per experiment. Data were shown as mean ± SEM. *: P < 0.05 vs
aCD3/aCD28 treatment groups.

Cr(VI) inhibits the secretion of IL-2, IL-4, and IL-10 by T cells
Once activated, T cells, mostly CD4+ T cells, secrete cytokines to regulate the
immune response. Certain cytokines, such as IL-2, IL-4, and IL-10, are critical in
anti-tumor immunity (Dennis et al., 2013, Fearon et al., 1990, Lee and Margolin,
2011). Therefore, the effects of Cr(VI) on their secretion were evaluated. As shown
in Figure 1.4, the levels of IL-2, IL-4, and IL-10 in the cell supernatant were
16

increased after stimulation with anti-CD3/anti-CD28 antibodies. Co-treatment of 2
or 5 µM Cr(VI) inhibited their secretion.
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Figure 1.4. Cr(VI) inhibits the secretion of IL-2, IL-4, and IL-10 by T cells.
The splenocytes were treated with 2 or 5 µM Cr(VI) plus anti-CD3 and anti-CD28
antibodies for 24 hours, the levels of IL - 2 (A), IL – 4 (B) and IL – 10 (C) in cell
supernatant were measured by ELISA. Data were shown as mean ± SEM. *: P <
0.05 vs aCD3/aCD28 treatment groups.
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Cr(VI) inhibits the cytolytic function of CD8+ T cells
Upon activation, CD8+ T cells exert their cytolytic function via degranulation, which
can be measured by their surface levels of CD107a via flow cytometry (Betts et al.,
2003). The same gating strategy was used as described above. Our data showed that
both 2 and 5 µM Cr(VI) significantly reduced CD107a levels on CD8+ T cells
compared to the those treated with only anti-CD3/CD28 antibodies, indicating an
inhibitive effect of Cr(VI) on the cytolytic function of CD8+ T cells (Figure 1.5).

19

Figure 1.5. Cr(VI) inhibits the cytolytic function of CD8+ T cells.
The splenocytes were treated with 2 or 5 µM Cr(VI) plus anti-CD3 and anti-CD28
antibodies for 24 hours, the levels of CD107a on CD8+ T cells were determined by
flow cytometry (A). Three independent experiments were conducted with triplicates
for each treatment group (B). Data were shown as mean ± SEM. *: P < 0.05 VS
aCD3/aCD28 treatment groups.

Discussion
In the present study, using the culture of mouse splenocytes as an in vitro model
system, we examined the effects of Cr(VI) on the viability as well as activation,
cytokine secretion and degranulation of splenic T cells. The dosages of Cr(VI),
which have been shown to affect human cells (Wise et al., 2016) (Vasant et al.,
2001), were chosen due to their relevance to occupational and environmental
exposures (Nemec et al., 2010). Our data show that Cr(VI) at 5 µM significantly
decreased the viability, inhibited activation, proliferation, cytokine secretion and
20

degranulation of T cells, which were marginally inhibited by 2 µM Cr(VI). The
results may reflect a threshold level of Cr toxicity considering that the maximum
contaminant level of Cr in drinking water was set by USEPA at 100 ppb (~1.92 µM).
T cell is a core component of host anti-tumor immunity. An efficient immune
response to destroy tumor cells requires the clonal expansion of both CD4+ and
CD8+ T cells after their activation. Increased numbers of CD4+ and CD8+ T cells are
found at the tumor site (Hadrup et al., 2013). Particularly, high numbers of CD8+ T
cells are linked to a better prognosis of patients with various types of cancer (Sato et
al., 2005, Fukunaga et al., 2004). Our results showed that Cr(VI) decreased the
expression of CD69 and CD25 on T cells in response to anti-CD3/CD28 antibodies
compared to non-treatment group, suggesting a compromised T cell activation by
Cr(VI) treatment (Figure 1.2). The data in Figure 1.3 further indicate that the
proliferation of both CD4+ and CD8+ T cells upon activation was inhibited by Cr(VI)
exposure, which is consistent with a previous report that
cobalt-chromium-molybdenum (CoCrMo) disc samples inhibited the proliferation of
human peripheral blood T lymphocytes in vitro (Faleiro et al., 1996).
Cytokines regulate the growth, differentiation, and activation of immune cells and
are involved in host anti-tumor immunity (Dranoff, 2004). Within T cell population,
they are predominantly secreted by CD4+ T cells (Green et al., 2007). Recently,
numerous studies have demonstrated that certain cytokines have broad anti-tumor
activity due to their capacity to directly stimulate immune effector cells at the tumor
site and enhance tumor cell recognition by cytotoxic effector T cells (Lee and
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Margolin, 2011). For example, IL-2 is known to stimulate the proliferation and
differentiation of CD4+ T cells and can enhance NK cell and CD8+ T cells function,
which engenders systemic anti-tumor immunity (Rosenberg, 2014). Other cytokines
such as IL-4 and IL-10 may also exert antitumor effects by enhancing
immunosurveillance and suppressing cancer-associated inflammation (Dennis et al.,
2013). Our data show that the secretion of IL-2, IL-4, and IL-10 was decreased by
48%, 57% and 35% upon 2 µM, and 65%, 81% and 51% upon 5 µM Cr(VI)
exposure, respectively (Figure 1.4). The decreased cell viability by Cr(VI) treatment
may potentially reduce the secretion of these cytokines, however, the viability of
CD4+ T cells was decreased by 13% and 17% by 2 or 5 µM Cr(VI), respectively
(Figure 1.1). These results suggest that Cr(VI) inhibit the secretion of the cytokines
in addition to inhibiting T cell viability.
Most tumor cells bear antigens that can be recognized by CD8+ T cells (Gajewski et
al., 2013). Upon activation, effector CD8+ T cells target the tumor cells and release
cytolytic granules containing perforin and granzyme to induce the apoptosis of these
cells, which represents an important anti-tumor effector function of CD8+ T cells and
is marked by an up-regulation of cell membrane level of glycoprotein CD107a (Betts
et al., 2003). Our data showed that Cr(VI) significantly decreased the expression of
CD107a on CD8+ T cells (Figure 1.5), suggesting an impaired anti-tumor effector
function of CD8+ T cells by Cr(VI).
In summary, our data suggest an immunotoxicity property of Cr(VI) as it decreased
the viability as well as inhibited the activation, proliferation, cytokine secretion and
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cytotoxic function of T cells. The suppression of T cell effector function by Cr(VI)
may induce immune escape and facilitate cancer development. The present in vitro
study set up a foundation for our further study to understand the mechanism
underlying Cr(VI)-induced immunosurveillance inhibition and carcinogenicity.

Acknowledgement
This article has been published in the journal Toxicology In Vitro in September,
2017.
L. Dai., W. Xu, H. Li., J.A. Frank., C. He, Z. Zhang and G. Chen. (2017). “Effects of
hexavalent chromium on mouse splenic T lymphocytes.” Toxicol In Vitro, 45,
166-171.

23

Chapter 2: Neonatal ethanol exposure causes behavioral deficits in young
mice

Synopsis
Background: Fetal ethanol (ETOH) exposure can damage the developing central
nervous system and lead to cognitive and behavioral deficits, known as fetal alcohol
spectrum disorders (FASD). ETOH exposure to mouse pups during early postnatal
days was used as a model of ETOH exposure that overlaps the human third-trimester
“brain growth spurt” - a model that has been widely used to study FASD in rats.
Methods: C57BL/6 male and female mice were exposed to ETOH (4 g/kg/day) on
postnatal days (PD) 4-10 by oral intubation. Behavioral testing of the offspring
included open field, elevated plus maze and Morris water maze with offspring tested
on PD 20 – 45.
Results: ETOH exposure during PD 4-10 resulted in hyperactivity, disinhibition, and
deficits in learning and memory in offspring with no apparent sex differences.
Conclusion: Based on these data, this neonatal mouse model may be useful for future
mechanistic and genetic studies of FASD and for the screening of novel therapeutic
agents.

Keywords
Fetal ethanol, behavior, development
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Introduction
Ethanol (ETOH) consumption during pregnancy can result in damage to the
developing central nervous system and lead to a variety of cognitive and behavioral
deficits including hyperactivity, disinhibition and deficits in learning, attention and
executive functions collectively known as the fetal alcohol spectrum disorders (FASD)
(Jacobson, 1998, Riley and McGee, 2005). Many mechanisms have been proposed to
help explain the consequences of EtOH's effects on the developing brain, but there are
still many unanswered questions.
Numerous animal models have been utilized in the study of FASD. Mouse models
have become increasingly useful due to the extensive knowledge of mouse genetics
for studies on the etiology of a variety of neurological disorders. Currently, the
number of studies using mice to study fetal ETOH effects has been limited and the
results are less reliable than in rat studies. In studies using a prenatal ETOH exposure
model, voluntary drinking throughout gestation has produced behavioral impairments
and deficits in tasks that tap into hippocampal function or sensorimotor integration,
although these data are not consistent (Allan et al., 2003, Becker et al., 1993, Brady et
al., 2012, Abbott et al., 2016). Prenatal ETOH exposure has also been assessed by oral
intubation to the pregnant dam with some studies reporting hyperactivity in
ETOH-exposed adolescent mice (Sanchez Vega et al., 2013, Fish et al., 2016), while
others report minimal effects on activity (Downing et al., 2009). Some studies have
focused on ETOH exposure during the early postnatal period. Olney and colleagues
have shown that a single postnatal ETOH injection can induce neuronal apoptosis
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(Ikonomidou et al., 2000) and may produce spatial deficits (Wozniak et al., 2004),
although there are some inconsistencies in this literature. Multiple injections of ETOH
to neonatal mice has been shown to alter performance on hippocampal and cerebellar
tasks (Bearer et al., 2015, Wagner et al., 2014) but this literature is far more limited
than that available with rat models.
The aim of the current study was to examine the effects of ETOH exposure during the
‘3rd trimester-equivalent’ in terms of human brain growth (Dobbing and Sands, 1979)
by oral intubation on FASD-related behaviors in C57BL/6 mice. ETOH was delivered
to the mouse pups on PD 4-10 by intubation. The offspring were then tested on PD
20-21 for activity levels using an open field, on PD 25-26 for exploration on an
elevated plus maze and on PD 35-45 for spatial learning and memory in a Morris
water maze.

Materials and Methods

Animals
Adult C57BL/6 mice were obtained from Harlan Labs (Indianapolis, IN). Offspring
were generated at the University of Kentucky Medical Center’s breeding colony. Male
and female pups, representing at least 8 litters from each treatment group, were used in
this study. Mice were maintained on a 14:10 h light-dark cycle (lights on at 07:00 h,
off at 21:00 h). All procedures were approved by the NIH and the Animal Care and
Use Committee of the University of Kentucky.

26

Breeding
Adult female and male C57BL/6 mice were caged in a ratio of 2:1 and seminal plugs
were examined the next morning as evidence that copulation occurred. If a seminal
plug was detected, it was designated gestational day (GD) 0 and the pregnant female
was singly housed.

Ethanol administration
ETOH was administered at 09:00 h to mouse pups on postnatal day (PD) 4-10 (as a
“3rd-trimester exposure” model) (Kelly et al., 1988). The day of birth was designated
PD 0. On PD 4, litters were weighed and pseudo-randomly culled to 6 pups
maintaining 3 males and 3 females when possible. These litters were then assigned to
one of three treatment groups: ETOH, intubated control (Maltose) or non-intubated
control (NTC). Pups in the ETOH group received 4 g/kg/day of ETOH on PD 4-10,
delivered via oral intubation (0.02 ml/g body weight) in an artificial milk solution
developed to nutritionally mimic rodent milk (Kelly and Lawrence, 2008). This dose
of ETOH was chosen because it has been shown to produce significant neurotoxicity
during the third-trimester equivalent and may lead to neurobehavioral deficits (Dursun
et al., 2013). Pups in the intubated control group received isocaloric maltose (in the
same milk solution) on PD 4-10. Pups were weighed daily and returned to their dam
immediately after intubations. Mortality from intubation was low (~ 5%).
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BEC measurement
For BEC of the pups, separate groups of pups were treated and trunk blood of pups
was collected on PD 7 following decapitation 30, 60, 90, 120, 180, 240, 360 and 480
min after ETOH intubation. BECs were determined using an assay kit from
Sigma-Aldrich, St. Louis, MO (product number: MAK076). The data were collected
from multiple samples (n=4) per time point.

Behavioral testing
Offspring were tested for activity in an open field (OF) for 2 days (between 08:00 –
12:00 h) on PD 20-22 (Mei et al., 2016), and for activity, anxiety and exploration in an
elevated plus maze (EPM) at similar times in the morning on PD 25–27 (Mei et al.,
2016). Offspring were then weaned on PD 28, housed with 2–3 same-sex littermates
and allowed to acclimate for one week prior to testing in the Morris water maze
(MWM). Spatial learning and memory in a MWM testing was conducted between
12:00– 16:00 h on PD 35-45 (Chen et al., 2013). These tasks and ages were selected to
assess the presence of behavioral impairments in both preweaning and adolescence, as
have been reported in clinical populations with FASD (Mattson et al., 2011). All
behavioral testing was conducted under low ambient light conditions with white noise
to reduce extraneous auditory stimuli. Surfaces and holding cages were cleaned before
and after testing with Nature’s Miracle© enzymatic cleaning solution to remove
animal odors. When males and females were tested on the same day, the males were
tested prior to females. Animal movements were recorded using the AnyMaze
tracking system (Stoelting Co.).
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Open Field (OF): OF testing is commonly used to measure levels of activity,
habituation to novel environments and patterns of exploration which may indicate
impulse control or anxiety (Bailey and Crawley, 2009). Each mouse was removed
from its home cage and brought into the test room in a clean holding cage for a 10-min
habituation period. The OF was a round chamber (diameter 39.4 cm) with opaque
white walls and floor. Subjects were tested 30 min daily for two consecutive days. The
dependent measures included total distance traveled and distance traveled in the
center. The center was defined as a circular zone in the center of the OF with a
diameter half of the width of the OF. Measurements related to activity in the center are
often used as a measure of anxiety and/or inhibitory control since mice typically
display thigmotaxis and avoid the center of open areas. Additional analyses were run
on center exploration when controlling for total distance traveled to produce a
preference score.
Elevated Plus Maze (EPM): EPM is primarily used as a test for anxiolytic agents
although it can also be used to measure exploration (Bailey and Crawley, 2009). The
EPM apparatus consisted of plus-shaped (+) Plexiglas maze with clear walls
bordering two of the four arms (30 x 6 cm). The mouse was placed halfway down one
open arm of the maze, facing away from the center, and was then allowed to explore
the maze for 5 min. Subjects were tested in a single session between PD 25-27. The
dependent measures included overall distanced traveled and distance traveled in the
open arms. Additional analyses were conducted looking at open arm exploration
controlling for total distance traveled.
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Morris Water Maze (MWM): MWM is used to measure spatial learning and retention
(Vorhees and Williams, 2006). The MWM consisted of a round plastic tub (diameter
107.6 cm) filled with water (22-23 ᵒC) made opaque using white non-toxic
water-based paint. A platform (15.2 x 15.2 cm) was submerged 0.75cm under the
surface of the water in a fixed location. Four visible extra-maze cues were placed at
various points around the maze. Each mouse was placed in one of four starting
positions on the far side of the pool (120, 150, 210 and 240ᵒ from the platform) and
allowed to swim until either they found the submerged platform or they reached a
ceiling of 60 sec. If they did not find the platform, they were gently guided to the
platform. Subjects remained on the platform for 5 sec before being removed for a 5
min intertrial interval (ITI). During maze acquisition, four trials were completed per
day for four days. On the fifth day, the platform was removed for a single probe trial.
The mouse was placed in the opposite quadrant and the swim pattern was recorded for
60 sec. Four hours after the probe trial, subjects were tested for reversal learning
which consisted of four trials with the platform replaced one quadrant away from its
original location. Following reversal learning (ITI 5 min), a single visible platform
trial was conducted where the platform’s location was indicated by a visible rod above
the surface of the water. The visible platform component was included to ensure that
there were no visual or motor deficits potentially contributing to performance on this
task following developmental ETOH exposure. MWM testing was conducted over 5
days between PD 35-45.
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The dependent measures during acquisition included latency to reach the platform and
distance traveled for each trial. For the probe trial, annulus crossings (the number of
crossings in the maze location where the platform was placed during acquisition
training) and the distance traveled in this region were recorded. For the reversal phase,
the dependent measures included latency to reach and distance traveled to the new
platform location. Similar measures were also recorded in the visible platform trial.

Statistical analysis
Data were analyzed using SPSS software version 21 (IBM). To avoid potential litter
effects, behavioral data from same-sex siblings were averaged together to produce a
single data point per sex, per treatment, per litter for each measure (Abbey and
Howard, 1973, Wainwright, 1998). Thus, each data point represented the mean of 2-3
same-sex siblings. For each analysis, univariate or mixed-factors analysis of variance
(ANOVA) was performed with treatment and sex as grouping factors and repeated
measures when warranted. Significant interactions were broken down by simple main
effect and/or post hoc Tukey test. The Greenhouse-Geisser correction was used to
correct for violations of homogeneity of variance when necessary. In some cases, this
correction resulted in degrees of freedom that were not whole numbers. If there was no
main effect or interaction with sex or across multiple time points (e.g. days, time bins,
etc), the data were collapsed across this variable for ease of presentation.
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Results

BEC and body weight
BEC levels of the separate group of pups were determined on PD 7 (see Figure 2.1).
BEC curves show a peak at 325.9 + 18.8 mg/dl for the pups with ETOH exposure.

Figure 2.1. BEC of ETOH treated pups.
BECs were measured at 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hours after the pups were
exposed to ethanol (4 g/kg, intragastric intubation) on PD 7. Data are expressed as
the mean ± S.E.M (n=4).

Offspring body weights on PD 4-10 are presented in Table 2.1. A mixed-factors
ANOVA demonstrated a significant interaction between treatment and age on weight,
F (3.06, 32.17) =10.84, p < 0.05. Post hoc tests indicated no significant difference in
body weights across groups on PD 4 – PD 9. ETOH exposure significantly decreased
body weight when compared with NTC only on PD 10.
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Table 2.1. Offspring weight profile during PD 4-10 and at the time of testing.

Table 2.1. The body weights of the pups in NTC, maltose and ETOH groups were
measured. *: p < 0.05 from the same sex counterparts in NTC. #: p < 0.05 versus
maltose-treated controls. Data are expressed as the mean (g) ± S.E.M, (n=8).

ETOH exposure also reduced body weight at the time of open-field and EPM testing
(Table 2.1). There were significant interactions between treatment and age, F (4, 54) =
3.69, p < 0.05, and sex and age, F (2, 54) = 4.86, p < 0.05. Therefore, post hoc tests
were conducted for males and females separately. For males, ETOH treatment
resulted in lower body weights for both OF and MWM, but not for EPM, relative to
maltose-treated controls (p < 0.05). Ethanol-treatment did not result in significant
differences in body weight compared to NTC. Additionally, maltose treated offspring
weighed more immediately prior to testing in MWM but did not differ from NTC
before OF and EPM testing. Among females, ETOH treatment resulted in a reduction
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in body weight at the time of OF testing in both NTC and maltose controls with no
body weight differences before EPM and MWM.

Behavioral testing
Open field: Neonatal ETOH exposure increased activity in the open field (see Figure
2.2). These data are shown collapsed across sex due to the lack of sex interactions with
treatment and the main effects of sex. The repeated measures ANOVA of distance
traveled revealed significant main effects of treatment, F (2, 43) = 11.99, p < 0.05 and
5 min block, F (2.67, 114.7) = 79.16, p < 0.05, with significant interactions of day by
block, F (3.89, 167.2) = 22.66, p < 0.05. Post hoc tests showed that on day 1 offspring
with ETOH exposure traveled further in OF across all time blocks relative to
maltose-treated controls (p < 0.05), and from bin 2 to 5 compared to NTC (see Figure
2.2A). On day 2, ETOH treated offspring were more active (i.e. traveled more
distance) across all time blocks than maltose-treated controls, while they were
traveled a greater distance from bin 2 to 6 relative to non-treated controls (p < 0.05)
(See Figure 2.2B).
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Figure 2.2. Total distance traveled in OF.
OF activity was assessed as distance traveled. Data is shown collapsed across sex,
displayed as two days with six 5-min time bins for each day. Asterisks (*) indicate a
significant difference from both NTC and maltose-treated controls. (#) indicates a
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significant difference from maltose-treated animals. (n=8 - 9) refers to the number of
litters represented per treatment group, with same-sex siblings averaged to represent
one data point.

Additional analyses assessed the effects of ETOH on center exploration and
preference, respectively measured as the total distance traveled in the center zone and
adjusted for the total amount of activity [(distance traveled in the center zone/total
distance traveled) x 100]. As expected, control mice avoided the center zone, with
only 19-20% of exploration typically occurring in this zone. ETOH treatment was
associated with increased distances traveled in the center zone, although this did not
reflect a greater preference for open spaces than controls but more reflected the
increased activity the ETOH exposed animals were displaying (see Figure 2.3). The
ANOVA on distance traveled in the center revealed a main effect of treatment, F (2,
43) = 7.99, p < 0.05, sex, F (1, 43) = 5.33, p < 0.05, day, F (1, 43) = 11.02, p < 0.05,
and a day by 5 min block interaction, F (5, 215) = 16.96, p < 0.05. Male mice explored
greater distance in the center than the females, but there was no sex by treatment
interaction. Post hoc tests showed that offspring with ETOH exposure explored
significantly more distance in the center than NTC or maltose-treated controls (p <
0.05) on day 1, but not on day 2 (p > 0.05). When adjusting these scores for the total
level of activity to create a preference score, a different pattern was apparent. There
were no significant differences across groups in center preference on either day 1 or
day 2 (see Figure 2.4).
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Figure 2.3. Total distance traveled in the center.
OF center exploration was assessed as distance traveled in the center zone. Data are
shown collapsed across sex and six 5-min time blocks. Asterisks (*) indicate a
significant difference from both controls. (n=8 - 9) refers to the number of litters
represented per treatment group.

Figure 2.4. Open field test center preference.
OF center preference was assessed as [(distance traveled in the center zone/total
distance traveled) x 100]. Data are shown collapsed across sex and six 5-min time
blocks. Asterisks (*) indicate a significant difference from both controls. (n=8 - 9)
refers to the number of litters represented per treatment group.
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Elevated plus maze: Neonatal ETOH exposure also produced hyperactivity in the
elevated plus maze relative to both the NTC and the maltose-treated controls (see
Figure 2.5A). The univariate ANOVA of distance traveled revealed a significant main
effect of treatment, F (2, 43) = 5.92, p < 0.05, with post hoc tests confirming these
findings.
The ETOH exposed offspring also showed increased exploration of open arms in the
EPM (see Figure 2.5B) and preference for the open arms of the maze (see Figure 2.5C),
respectively. Univariate ANOVA for distance traveled in the open arms showed a
main effect of treatment, F (2, 43) = 19.19, p < 0.05, with post hoc tests showing that
ETOH treatment increased the distance traveled in the open arms relative to both
controls (p < 0.05). The univariate ANOVA of preference scores also yielded a
significant main effect of treatment, F (2, 43) = 15.40, p < 0.05. As expected, control
mice avoided the open arms, with 27% (NTC) of exploration typically occurring in
these areas of the maze. ETOH treatment increased open arm preference relative to
both controls (p < 0.05). This effect consisted of a ~15% increase in open arm
preference with ~42% of all exploration occurring in the open arms.

38

Figure 2.5. Elevated plus maze test.
EPM activity and exploration were assessed as the total distance traveled (A), the
distance traveled in open arms (B) and open arm preference (C), measured as (the
distance traveled in the open arms/the total distance traveled) x 100. Data are shown
collapsed across sex. Asterisks (*) indicate a significant difference from both
controls (n=8).

Morris water maze: Both the distance (see Figure 2.6A) and the latency (see Figure
2.6B) traveled to reach the platform were impaired following neonatal ETOH
exposure. The mixed-factors ANOVA of distance traveled to the platform revealed a
significant main effect of day, F (3, 123) = 34.82, p < 0.05, and treatment, F (2, 41) =
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18.73, p < 0.05. Post hoc tests confirmed that offspring with ETOH treatment traveled
a greater distance to find the platform (p < 0.05) relative to both controls. The
mixed-factors ANOVA of escape latency revealed a significant main effect of
treatment, F (2, 41) = 11.30, p < 0.05, and day, F (3, 123) = 17.47, p < 0.05. Post hoc
tests confirmed that ETOH exposed group took longer to find the platform than
controls (p < 0.05). A subset of mice failed to learn to swim to the platform during
acquisition, often floating rather than searching for the platform. Failure to acquire the
task was defined as the failure to reach the platform on all 4 trials on acquisition day 4.
Neonatal treatment did not significantly influence the number of mice that failed to
meet the criterion. Adjusted sample sizes for MWM analyses with the removal of
subjects unable to acquire the task still represented data from 8-9 litters of mice.
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Figure 2.6. Morris water maze acquisition phase.
Spatial learning in the MWM was measured as a reduction in the distance (A) and
latency (B) traveled prior to escaping onto the platform over four days of training.
Asterisks (*) indicate a significant group difference from both controls across time
points. (n=8-9) refers to the number of litters represented per treatment group.

For the probe trial, there was also a significant main effect of treatment, F (2, 41) =
3.66, p < 0.05. Post-hoc analyses revealed a reduction in the number of annulus
crossings in the ETOH exposed offspring compared to maltose controls (p < 0.05), but
not NTC (p > 0.05) (see Figure 2.7).
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Figure 2.7. Morris water maze probe trial.
The number of annulus crossings was measured in the probe trial. (#) indicates a
significant difference from maltose-treated animals. (n=8-9) refers to the number of
litters represented per treatment group.

Performance on the reversal component of the MWM is shown in Figure 2.8. There
was a main effect of treatment, F (2, 41) = 6.47, p < 0.05, and day, F (3, 123) = 14.79,
p < 0.05 with the ETOH exposed offspring taking longer to reach the platform than
the controls (see Figure 2.8A). There were no significant interactions or main effects
on the distance traveled to reach the platform (see Figure 2.8B).
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Figure 2.8. Morris water maze reversal learning.
Reversal learning of MWM was tested by shifting the platform to a novel location
and the latency (A) and distance (B) of escape onto the platform was measured.
Asterisks (*) indicate a significant difference from controls (n=8).

All treatment groups performed similarly on the visual platform component of the
MWM. Figure 2.9. showed the swimming speed of all groups in the visual platform
trial.
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Figure 2.9. Morris water maze visual platform.
The swimming speed of escape onto the platform was measured in a single visual
platform trial. No significant difference was observed (n=8).

Discussion
Behavioural defects are typically observed in children with FASD and serve as an
important tool for diagnosis and treatment of FASD. Different timing and dosages of
alcohol exposure will produce different behavioral phenotypes in children. For
example, the brain growth spurt is a critical period when the central nervous system
undergoes rapid growth and synaptogenesis (Girard et al., 2001). Alcohol exposure
during this period has been reported to impair spatial learning in both rats and mice
(Lewis et al., 2007, Furumiya and Hashimoto, 2011). Of interest, there is a disparity
in brain development between human and rodents. In human, brain growth spurt
happens during the third-trimester, while in rodents, it happens during the early
postnatal days (Semple et al., 2013). Therefore, this study was designed to investigate
the effects of early postnatal ETOH exposure on activity in an open-field, the elevated
plus maze and spatial learning and retention in a Morris Water Maze in male and
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female C57BL/6 mice. Our results showed that neonatal ETOH exposure resulted in
hyperactivity, disinhibition, and deficits in learning and memory in the offspring with
no sex differences observed. These results are similar to those in clinical studies and
so provide strong face validity for this mouse model of FASD. The effects observed in
our study are also very similar to those that have been reported in a variety of rat
models for fetal ETOH effects, including those based on gestational exposure alone
(Carneiro et al., 2005, Hofmann et al., 2005), postnatal exposure alone (Green et al.,
2007, Lewis et al., 2012), and combined pre and postnatal exposure (Cronise et al.,
2001, Brocardo et al., 2012), and so provide strong support for this mouse model.

Hyperactivity appeared to be a consistent finding in two different paradigms (OF and
EPM) and at two different ages in the current study. This suggests that this effect is
persistent at least in the young mouse. Hyperactivity is one of the more frequently
observed behavioral characteristics in both rodent models and in clinical populations
with FASD and represents a key focus of drug development efforts for FASD (Koren,
2015).
In addition to activity, both the OF and EPM tasks used in the current study included a
component typically used to assess anxiety; the open arms of the EPM and the center
region of the OF. Mice generally avoid these open areas and control mice displayed
this species-typical behavior. ETOH exposure increased exploration in these open
areas, although interpretation was complicated by the fact that these offspring were
hyperactive. To better understand this pattern, activity in the open areas was assessed
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relative to total activity for each subject and this lead to different patterns on the two
tasks. For the OF, the ETOH exposed mice were equally hyperactive in the periphery
and in the center and so the increased exploration in the center was probably best
explained as hyperactivity. In contrast, EPM exploration showed open arm preference
approaching 50%, suggesting no real preference or avoidance for the open arms.
These EPM findings are consistent with previous studies using young rats with early
ETOH exposure (Carneiro et al., 2005).
The disparity in ETOH effects on open area exploration in the OF and EPM is
interesting. Although these open areas are both aversive, previous studies suggest that
the EPM may be more sensitive to anxiolytic or disinhibitory effects than the OF
(Schmitt and Hiemke, 1998, Acevedo et al., 2014), possibly due to the unique
combination of open spaces and raised elevation in the EPM (Schmitt and Hiemke,
1998). The results from the current study provide support for the hypothesis that
hyperactivity and reduced open space avoidance may represent functionally distinct
forms of inhibitory deficits in mice (Carola et al., 2002). From an ecological
perspective, the failure of a rodent to avoid open spaces would lead to a higher “risk”
of predation, suggesting that the observed ETOH effects could have real implications
for natural consequences. These inhibitory failures may be an important feature of the
present mouse model, as those with FASD have difficulty avoiding risky behaviors or
aversive consequences, leading to poorer outcomes through childhood and
adolescence (Green et al., 2007) into adulthood (Moore and Riley, 2015). Although
the present data do not implicate specific inhibitory control mechanisms which impact
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decision making (Bari and Robbins, 2013), future testing with this model may use
more sophisticated tests of executive function to parse out these factors.
ETOH exposure also impaired acquisition of the MWM spatial task. Offspring with
ETOH exposure had longer swim paths and greater latencies to reach the platform
during acquisition of the task. These differences were not observed in the visible
platform trial, so the differences in performance displayed by the ETOH exposed
offspring relative to the controls could not be due to swimming deficits. Treatment
effects were not evident in the first trial, but once evident, were consistent across
acquisition. This did not translate to altered behavior during the probe trial relative to
non-treated controls. Given this pattern, the observed performance impairments may
be interpreted as impairments in spatial learning. These findings are consistent with
previous 3rd-trimester ETOH exposure rodent models reporting deficits in MWM
acquisition (Goodlett and Peterson, 1995, Banuelos et al., 2012, Wagner et al., 2014).
Deficits in memory and spatial abilities are also commonly reported among clinical
populations with fetal ETOH exposure (Doyle and Mattson, 2015) and also represent
key targets for intervention.
There were no observable sex differences in outcome as a function of neonatal ETOH
exposure. Previous mouse studies with relatively brief, 1 or 3 days, postnatal ETOH
exposure paradigms have similarly shown little or no sex differences with one
exception after a 2-day binge that was limited to the probe trial (Wagner et al., 2014).
In addition to the overlap in behavioral characteristics displayed by these offspring to
rat and clinical studies, the advantage of this mouse intubation model over injection is
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that it avoids potential tissue damage and ETOH leakage due to the porous skin
(Moser et al., 2005). Moreover, intubation allows for a more consistent and better
controlled BEC level in the offspring. It should be noted that a relatively high BEC
was used in the current study as previous studies have emphasized the importance of
peak BECs in ETOH’s behavioral teratogenicity (Kelly et al., 1987) and that higher
BECs, as the BECs observed in this study, are typically required for persistent
behavioral effects (Allan et al., 2003). Nevertheless, these high BEC levels are
comparable to those reported in human alcoholics (Urso et al., 1981, Jones and
Harding, 2013) and those used in rodent models (Goodlett et al., 1990).
In conclusion, the current early postnatal ETOH intubation paradigm resulted in
hyperactivity, disinhibition, and deficits in learning and memory in the young mice
with no apparent sex difference. These behavioral deficits are most likely the
consequences of ethanol-induced damage to the developing brain. Normal
developmental signaling in neurons (Luo, 2009) and glial cells (Costa et al., 2004) has
been shown to be disrupted by neonatal ethanol exposure. The disruption may lead to
mal-development of certain brain areas that are sensitive to ethanol exposure, such as
the prefrontal cortex, corpus callosum, hippocampus and cerebellum, which control
the functions of activity, learning, and memory (Alfonso-Loeches and Guerri, 2011).
Therefore, the current mouse model can be useful for further studying the molecular,
cellular and genetic mechanisms underlying ethanol-induced behavioral deficits in
FASD.
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Chapter 3: The effects of early ethanol exposure on behavioral
consequence in young mice

Synopsis
Background: Fetal alcohol spectrum disorder (FASD) is an umbrella term for a range
of cognitive and behavioral defects in children with prenatal alcohol exposure. The
behavioral consequences resulted from the early ETOH exposure are important for
diagnosis and drug development of FASD and largely depend on the timing, dose,
and avenue of ETOH administration.
Methods: The current study utilized prenatal DID (Drinking in the Dark) and
postnatal intubation procedures alone or in combination to produce five ETOH
exposure paradigms. Behaviors of C57BL/6 mice were assessed through an open
field, elevated plus maze and Morris water maze tests on PD 20 – 45.
Results: Our results showed that postnatal ETOH exposure with or without prenatal
treatment resulted in hyperactivity, disinhibition, and deficits in spatial learning and
memory in C57BL/6 mouse offspring.
Conclusion: By employing different timing, dosages, and methods of ETOH delivery,
our results provided an inclusive aspect on how early ETOH exposure may affect
behavioral consequences in mice, which serves as a solid base for the further
investigation on the neurogenesis mechanism underlying the FASD.
Keywords
FASD, C57BL/6 mice, DID, behavioral deficits
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Introduction
Maternal alcohol ingestion during pregnancy may cause a spectrum of
morphological anomalies and behavioral deficits in the offspring, known as fetal
alcohol spectrum disorders (FASD) (Wilhelm and Guizzetti, 2015). The children
affected by fetal alcohol exposure display a series of cognitive and behavioral
abnormalities such as impulsive behaviors and hyperactivity, as well as deficits in
learning and memory (Kable et al., 2016).
In order to investigate the neurogenetic mechanisms underlying FASD and seek the
therapeutic targets, a number of animal models, including mice and rats, have been
developed. Compared to rats, mice better meet the demands for genetic manipulation
and testing, given the broad understanding of mouse genetics. Additionally,
behavioral consequences of fetal alcohol exposure vary by timing, dosage, and
methods of ETOH delivery (Kelly et al., 2009). For example, M.L. Kleiber exposed
C57BL/6J dams to 10% ETOH in water via the two-bottle method across the
gestational period (Kleiber et al., 2011). ETOH treated pups showed less activity
than the controls, while no behavioral abnormalities were detected among ETOH
exposed offspring when mice were treated with 3 g/kg ETOH from G7-G18 through
intragastric intubation (Downing et al., 2009).
The purpose of the current study was to test the effects of early ETOH exposure on
C57BL/6 mice behaviors by manipulation of timing, dose and ETOH administration.
ETOH was delivered to the pregnant dams via a method named “Drinking in the
Dark” (DID) (Moore et al., 2007, Rhodes et al., 2005), to the pups through
51

intubation from PD 4-10, or both combined. The activity, exploration and spatial
learning of the offspring were then tested using an open field and an elevated plus
maze for preweaning animals and Morris water maze when they reached
adolescence.

Materials and Methods

Animals
The adult male and female C57BL/6 mice were purchased from Harlan Labs
(Indianapolis, IN) and used as breeders for this study. All animals were housed in the
animal facility of the University of Kentucky Medical Center. All procedures were
approved by the NIH and the Animal Care and Use Committee of the University of
Kentucky. The breeding facility was maintained on a reversed light cycle, so
experimental procedures including drinking in the dark and postnatal exposure were
carried out in the dark. Dim red lighting was used when experimenters were present
to avoid disruptions to the light cycles of the mice. A dark anti-room adjacent was
used to allow experimenters to enter the dark procedure room without outside light
exposure. Behavior tests were conducted in the light.

Breeding and maternal treatment
Approximately 10 weeks old, female mice were individually housed and acclimated
to a 12-hour reverse light/dark cycle (lights on at 2100 h, off at 0900 h) for one week
prior to the drinking in the dark session. Once the session started, female mice were
randomly assigned to the water or ethanol group. Three hours into the dark cycle
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(0900), mice in the ethanol group were only given access to ethanol (20% v/v in
water) in a sipper-tube for 2 hours (1200 h – 1400 h) per day for the first three days
and then for 4 hours (1200 h – 1600 h) per day for a week. The control group mice
were given access to water only. Following one week of 4-hour DID adaptation,
individual females were placed into the cage of singly housed males for mating for
two hours from 1600 h –1800 h and returned to their home cages. The DID sessions
continued throughout the entire gestation. Vaginal plugs were examined early the
next morning as evidence that copulation occurred.
To avoid the possible negative effects of continued maternal ethanol intake and
withdrawal from maternal ethanol intake on litter care, the period of ethanol intake
was shortened to 90 min on the postnatal day 0 (the day of birth), 60 min on PD 1,
and 30 min on PD 2. DID sessions no longer employed on PD 3, or any day
thereafter (Boehm et al., 2008).

Postnatal treatment
On PD 4, offspring with or without prenatal ETOH treatment were weighed and
randomly assigned to either a postnatal ETOH intubation or a non-intubated group.
To preclude potential litter effects, male and female pups, representing at least 8
litter for each treatment group were used. Pups in the postnatal ETOH group
received either 3 g/kg/day or 4 g/kg/day of ETOH delivered via oral intubation in the
water on PD 4–10. These doses were chosen because they have been shown to
produce significant neurotoxicity during the third-trimester equivalent and may lead
to neurobehavioral deficits (Dursun et al., 2013). The non-intubated group received
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no treatment. The pups were returned to the dam and allowed to nurse immediately
after intubations. Pup body weights were recorded daily. Mortality from intubation
was low (approximately 5%). The maternal and postnatal ETOH treatments were
shown in Table below.
Table 3.1. Treatment Strategy.

Table 3.1. Pregnant dams received either no treatment or DID during the entire
gestational period. Their offspring were treated with water, 3 g/kg, or 4 g/kg ETOH
from PD 4-10, which produced 5 treatment paradigms in total.

BEC measurement
For BEC of pregnant dams, blood samples were obtained from a 1-2 mm tail clip
following 4 hours DID period. For BEC of the pups, separate groups of pups were
treated and trunk blood of pups was collected on PD 4 or PD 10, following
decapitation 30, 60, 90, 120, 180, 240, 360 and 480 min after ETOH intubation. BEC
was determined using an assay kit from Sigma-Aldrich, St. Louis, MO (product
number: MAK076). The data were collected from multiple samples (n=4) per time
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point as shown in Figure 3.1

Behavioral testing
Open Field (OF): The OF was a round chamber (diameter 39.4 cm) with opaque
white walls and floor, which is commonly used to test levels of activity, impulse
control or anxiety (Bailey and Crawley, 2009). The center was defined as a circular
zone in the center of the OF with a diameter half of the width of the OF. Since mice
typically display thigmotaxis and avoid the center of open arenas, OF center
exploration is often used as a measure of anxiety and/or inhibitory control. On PD
20-22, the activity of offspring in an open field was tested 30 mins daily for two
consecutive days in the morning between 08:00 – 12:00 (Mei et al., 2016). The
measurements included the total distance traveled, distance traveled in the center and
the number of entries into the center.
Elevated Plus Maze (EPM): The EPM is a plus-shaped (+) Plexiglas maze with clear
walls bordering two of the four arms (30 x 6 cm). It is typically used to evaluate the
impulse control and /or anxiety issues of mice (Bailey and Crawley, 2009). On PD
25–27, the exploration of each subject in the EPM was tested for 5 mins. The
distance traveled overall, distance traveled in the open arms and the number of open
arm entries was measured.
Morris Water Maze (MWM): MWM is a round plastic tub with a diameter of 107.6
cm, which is used to measure spatial learning and memory (Vorhees and Williams,
2006). Four visible extra-maze cues were placed around the tub at various points. A
platform (15.2 x 15.2cm) was submerged 0.75cm under the surface of the water in a
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fixed location. On PD 35 -45, the performance of offspring in MWM was tested
between at 12:00 – 16:00 h (Chen et al., 2013). During maze acquisition, four trials
were completed per day for four consecutive days. For each trial, each mouse was
placed in one of four starting positions on the far side of the pool (120, 150, 210 and
240ᵒ from the platform) and allowed to swim until either it found the submerged
platform or reached a ceiling of 60 secs. If it did not find the platform, it was gently
guided to the platform. Subjects remained on the platform for 5 sec before being
removed for a 5 min intertrial interval (ITI). The latency and distance traveled for
each mouse per trail were recorded. On the fifth day, a single probe trial was
conducted. The platform was removed and the mouse was placed in the opposite
quadrant. The number of annulus crossings was recorded for 60 sec. Four hours after
the probe trial, the platform was moved to one quadrant away from its original
location for a reversal learning test. Four trials in total were conducted as described
in the acquisition phase. The distance and latency traveled before each mouse
escaped on the platform were recorded. Following reversal learning (ITI 5 min), a
single visible platform trial was conducted with a visible rod placed on the top of the
platform to indicate its location. The visible platform component was included to
ensure that there were no visual or motor deficits potentially contributing to
performance on this task following developmental ETOH exposure.
All behavioral tests above were conducted under low ambient light conditions with
white noise to reduce extraneous auditory stimuli. Nature’s Miracle© enzymatic
cleaning solution was used to clean the surfaces and holding cages to remove animal
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odors before and after testing. When males and females were tested on the same day
for the same behavioral tests, the males were tested first. Animal movements were
recorded using the AnyMaze tracking system (Stoelting Co.)

Statistical Analysis
SPSS software version 21 (IBM) was used to analyze all data. To avoid potential
litter effects, behavioral data from same-sex siblings were averaged together to
produce a single data point per sex, per treatment, per litter for each measure (Abbey
and Howard, 1973, Wainwright, 1998). Thus, each data represents the mean of 2-3
same-sex siblings. Univariate or mixed-factors analysis of variance (ANOVA) was
performed with treatment and sex as grouping factors followed by post hoc Tukey
test. The Greenhouse-Geisser correction was used to correct for violations of
homogeneity of variance when necessary. In some cases, this correction resulted in
degrees of freedom that were not whole numbers. If there was no main effect or no
interaction between treatment and sex or multiple time points (e.g. days, time bins,
etc), the data were averaged across this variable for ease of presentation and higher
statistical power.

Results

BEC and body weight
Over the course of gestation, pregnant dams in the DID group had free access to
20% EtOH solution for 4 hours during the early dark cycle. They consumed a range
of 5.3 – 8.2 g/kg with an average of 6.58 g/kg EtOH per day and had an average
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BEC of 0.751 mg/ml. BEC levels of pups that received 3 g/kg or 4 g/kg ETOH alone
were determined on PD 4 and PD 10, respectively. All BEC curves peaked at 1 hour
post-intubation with a value of 235.3 ± 17.63 and a value of 325.7 ± 22.49 for
postnatal 3 g/kg or 4 g/kg ETOH treatment, respectively on PD 4 (Figure 3.1A), a
value of 210.5 ± 16.5 and a value of 307.2 ± 25.6 correspondingly on PD 10 (Figure
3.1B).

Figure 3.1. BECs of postnatal ETOH treated offspring.
BECs were measured at 30, 60, 90, 120, 180, 240, 360 and 480 after ETOH
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intubation (3 g/kg or 4 g/kg) on PD 4 (Figure 3.1A) and PD 10 (Figure 3.1B). BECs
peaked at approximately 1 hour post intubation. Data are expressed as mean ± S.E.M
(n=5).

Body weights of pregnant dams were recorded every 5 days from GD 0 to GD 20. A
mixed factors ANOVA showed a significant main effect of day, F (4, 70) = 1291.92,
P < 0.05, and a day by treatment interaction, F (4, 70) = 8.98, P <0.05. No significant
effects of dam treatment on body weight gain (Figure 3.2) or litter size were
observed.

Figure 3.2. Body weight gain of pregnant dams.
Body weights of pregnant dams in both control and DID treated groups were
recorded every 5 days from GD 0 to GD 20. Data are expressed as mean ± S.E.M
(n=14).

Body weights of newborn offspring were recorded daily from PD 4 to PD 10. There
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was a significant effect of treatment, F (5, 42) = 5.53, P < 0.05, age, F (1.75, 73.31)
= 17971.57 and an interaction between age and treatment, F (8.73, 73.31) = 10.65 P
< 0.05. Post hoc analysis showed combined maternal DID and postnatal 4 g/kg
EtOH weighed less than control on PD 5-10. Mice treated with 4 g/kg ETOH alone
weighed less than control on PD 8-10 (Table 3.2). ETOH treatment at 3 g/kg dose
alone or in combination with maternal DID did not affect the body weights of the
offspring.
Offspring were so weighed on the day of behavioral testing. There were significant
effects of treatment, F (5, 86) = 4.65, P < 0.05 and sex, F (1, 86) = 34.18, P < 0.05 on
body weights. Post hoc tests showed that female offspring with combined maternal
DID and postnatal 4 g/kg EtOH weighed less than 3 g/kg treatment alone on the day
of MWM testing.
Table 3.2. Body weights of offspring on PD 4-10 and at the time of behavioral
testing.
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Table 3.2. The body weights of offspring were recorded every day from PD 4 to PD
10, as well as on the day of each behavioral test. The data are presented as mean ±
S.E.M. *: p <0.05 as compared with controls (n=8).

Behavioral testing
Open field: An analysis of OF exploration revealed that offspring in both groups that
received postnatal 4 g/kg ETOH were more active relative to controls. Maternal DID
did not affect activity levels alone or alter the effect of postnatal exposure. Figure 3.3
shows activity in the OF as measured by distance traveled over two OF sessions. The
mixed factors ANOVA of distance traveled revealed significant main effects of
treatment, F (5, 100) = 14.33, p < 0.05, day, F (1, 100) = 27.15, p < 0.05, and time
bin, F (3.62, 362.24) = 248.18, p < 0.05, with significant interactions of day by
treatment, F (5, 100) = 2.35, p < 0.05, and bin by treatment, F (18.12, 362.24) = 1.83,
p < 0.05, as well as an interaction of day, bin and treatment, F (20.68, 413.51) = 1.91,
p < 0.05. Post hoc tests showed that offspring with postnatal ETOH exposure of 4
g/kg, with and without maternal DID, traveled more distance across multiple time
blocks within each session relative to controls (p < 0.05). Maternal DID, postnatal 3
g/kg, and their combination did not significantly alter distance traveled in the OF.
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Figure 3.3. Distance traveled across time in the open field.
Postnatal ETOH exposure of 4 g/kg, with and without maternal DID were
hyperactive on both OF sessions. Data is presented, collapsed across sex, as total
distance traveled in the OF (mean ± S.E.M). *: p <0.05 as compared with controls
(n=8-12 liters per treatment group).
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Additional analyses assessed ETOH effects on center exploration, measured as the
total distance traveled in the center zone and number entries into the center. Postnatal
ETOH treatment of 4 g/kg ETOH was associated with a greater distance traveled in
the center zone, although this did not reflect a greater likelihood of entering the
center. For center exploration, there were significant main effects of treatment, F (5,
100) = 8.21, p < 0.05, sex, F (1, 100) = 7.22, p < 0.05, and day, F (1, 100) = 30.74, p
< 0.05, but no interactions with day. Post hoc tests showed that offspring with
postnatal exposure to 4 g/kg ETOH explored a significantly greater distance in the
center than controls (p < 0.05) (Figure 3.4). No group differences or interactions
were detected on the number of entries into the center (Figure 3.5).

Figure 3.4. Distance traveled in the center of open field.
Postnatal ETOH treatment of 4 g/kg, regardless of prenatal treatment, traveled a
greater distance in the center zone relative to controls on both test days. Data is
shown, collapsed across sex and 5-min time block for each day (mean ± S.E.M). *: p
<0.05 as compared with controls (n=8-12 liters per treatment group).
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Figure 3.5. The number of entries into the center of open field.
No difference was observed among groups in respect to the number of entries into
the center. Data is shown, collapsed across sex and 5-min time block for each day
(mean ± S.E.M).

Elevated plus maze: ETOH effects were observed on both total activity level and the
tendency to explore open areas in the EPM, with combined DID and postnatal 4 g/kg
ETOH treatments showing the most robust effects across these measures. Figure 3.6
shows performance in the EPM, as measured by distance traveled (Figure 3.6A) and
open arm exploration (Figure 3.6B and C). The univariate ANOVA of distance
traveled in the EPM revealed a significant main effect of treatment, F (5, 97) = 5.83,
p < 0.05, with post hoc tests confirming that offspring with combined maternal DID
and postnatal 4 g/kg ETOH were more active (p < 0.05) relative to controls. No
other treatment groups reached significance on this measure.
Additional analyses assessed ETOH effects on open arm exploration, measured as
the distance traveled in (Figure 3.6B) and the number of entries into (Figure 3.6C)
the open arms of the maze. ETOH exposure dose-and time-dependently increased
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both explorations of the open arms and the number of entries, although the patterns
for these two measures differed somewhat. Univariate ANOVA for distance traveled
in the open arms showed a main effect of treatment, F (5, 97) = 12.28, p < 0.05, with
post hoc tests showing that the combination of maternal DID and postnatal ETOH
treatment (either 3 or 4 g/kg) increased distance traveled in the open arms relative to
controls, (p < 0.05). Of interests, offspring with combined DID and postnatal
treatment of 4 g/kg also traveled greater distances in the open arms than offspring
with postnatal 4 g/kg alone. The univariate ANOVA of open arm entries yielded a
significant main effect of treatment, F (5, 97) = 4.70, p < 0.05. Post hocs showed that
postnatal 4 g/kg ETOH treatment increased open arm entries relative to controls (p <
0.05), with and without maternal DID.

65

Figure 3.6. Elevated plus maze test.
Offspring exposed to the combined maternal DID and postnatal 4 g/kg ETOH were
more active relative to controls (Figure 3.6A). Offspring with the combination of
maternal DID and postnatal ETOH treatment (either 3 or 4 g/kg) traveled a greater
distance in the open arms relative to controls (Figure 3.6B). Postnatal ETOH
treatment of 4 g/kg increased open arm entries relative to controls (Figure 3.6C). The
data is presented, collapsed across sex (mean ± S.E.M). *: p <0.05 as compared with
controls (n=8-11 liters per treatment group).

Morris water maze: Offspring exposed to postnatal ETOH exposure, independent of
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prenatal exposure, showed impaired acquisition in the MWM. Acquisition
performance was measured by the latency and distance traveled prior to escape
(Figure 3.7) onto the platform. The mixed-factors ANOVA of escape latency
revealed a significant main effect of treatment, F (5, 97) = 8.07, p < 0.05, and day, F
(2.60, 251.70) = 57.62, p < 0.05. Post hoc tests confirmed that those groups exposed
to 4 g/kg ETOH postnatally, with or without maternal DID, as well as those
receiving 3 g/kg postnatally, required more time to find the platform (p < 0.05)
relative to controls. A similar trend among those with combined maternal DID and
postnatal 3 g/kg failed to reach significance. The mixed-factors ANOVA of distance
traveled to the platform revealed a significant main effect of treatment, F (4, 67) =
4.78, p < 0.05, and day, F (2.68, 259.80) = 104.88, p < 0.05. Post hoc tests confirmed
that those groups with postnatal ETOH exposure with 4 g/kg ETOH, with or without
maternal DID, traveled further to reach the platform than controls (p < 0.05).
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Figure 3.7. Morris water maze test acquisition.
Offspring exposed to 4 g/kg ETOH postnatally, regardless of prenatal treatment, as
well as those receiving 3 g/kg, took longer to find the platform (A). Mice with
postnatal 4 g/kg ETOH treatment also traveled a longer distance than controls prior
to escape onto the platform (B). The data is presented, collapsed across sex and 4
daily acquisition trials (mean ± S.E.M). *: p <0.05 as compared with controls
(n=8-12 liters per treatment group).

For the probe trial, there was a significant main effect of treatment, F (5, 109) = 4.11,
p < 0.05. Post-hoc analysis revealed that there was a reduction in the number of
annulus crossing in offspring with postnatal 4 g/kg ETOH treatment alone and when
combined with maternal DID (p < 0.05). A similar trend among offspring with
postnatal exposure to 3 g/kg ETOH failed to reach significance (p= .06) (Figure 3.8).
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Figure 3.8. Morris water maze probe trial.
Offspring exposed to 4 g/kg ETOH with or without prenatal treatment showed a
reduction in the number of annulus crossing (mean ± S.E.M). *: p <0.05 as
compared with controls (n=8-12 liters per treatment group).

Performance on the reversal component of the MWM is shown in Figure 3.9.
Postnatal ETOH exposure alone increased escape latencies in the reversal phase
relative controls. Escape latency is presented in Figure 3.9A. There was a main
effect of treatment, F (5, 97) = 5.62, p < 0.05. Post-hoc analysis revealed that that
offspring with postnatal 4g/kg ETOH treatment alone and when combined with
maternal DID took longer to reach the platform than controls (p < 0.05). There were
no significant treatment effects on the distance traveled to the platform (see Figure
3.9B).
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Figure 3.9. Morris water maze reversal learning.
Offspring with postnatal 4 g/kg ETOH treatment alone or combined with maternal
DID took longer to reach the platform than controls during the reversal phase of the
MWM (A), but no difference was observed among groups in respect to the distance
traveled to the platform (B). The data is presented, collapsed across sex (mean ±
S.E.M). *: p <0.05 as compared with controls (n=8-12 liters per treatment group).

To assess whether early ETOH exposure altered motor performance or visual ability,
swim speed was measured in a visible platform probe (Figure 3.10). There were no
significant effects of treatment on swim speed to reach the visible platform. A sex
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effect was detected, F (5, 109) = 5.62, p < 0.05, whereby females swam faster than
males.

Figure 3.10. Morris water maze a visual platform trial.
No difference was shown in the swimming speed among groups in the single visual
platform trial. The data is presented, collapsed across sex (mean ± S.E.M).

Discussion
The current study aimed to characterize key behavioral phenotypes across early
development with different methods, dosage and timing of ETOH delivery. In doing
so, maternal DID and postnatal intubation procedures were used alone or in
combination to produce five ETOH exposure paradigms. ETOH exposure effects on
behavioral performance were detected. Since our previous study showed that there
was no significant difference between non-treated control and maltose intubated
control in respect to behavioral consequences (seen in project 2), this current study
did not include the maltose-intubated group as an isocaloric control.
Maternal DID was found to lead to a BEC of approximately 100 mg/dl. However,
the moderate levels of ETOH exposure produced by DID have not been shown to
produce robust behavioral impairments across in juvenile or adolescent mice, either
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in the current study or in previous work by Boehm et al (Boehm et al., 2008). By
contrast, each of the doses of ETOH selected for postnatal intubation resulted in
peak BECs exceeding 200 mg/dl. Of these, only the 4 g/kg dose produced high
BECs that remained above 200 mg/dl for over two hours, a pattern associated with
behavioral impairments in existing models. Postnatal ETOH intubation paradigms
have rarely been reported in mice, although they are preferable methods to repeated
injections which may lead to increased ETOH leakage from the pups’ porous skin
(Moser et al., 2005). The pharmacokinetic and behavioral data presented here, as
well as strong rates of pup survival (<5% mortality), support the continued use of
postnatal intubations to model 3rd-trimester ETOH exposure in mice. Additionally,
the weight gain of dams and pups was unaffected by maternal DID alone. Offspring
exposed to 4 g/kg or combination of DID with 4 g/kg ETOH weighed less than
controls on early postnatal ages. Even so, the present data do suggest that these
sub-threshold ETOH exposures may contribute to greater effects for postnatal
treatments, as DID and 4 g/kg showed weight reductions earlier than pups with
postnatal 4 g/kg ETOH alone.
In the current study, prenatal treatment, postnatal treatment or their combination may
alter performance on a number of behavioral outcomes. OF and EPM were
conducted in preweaning mice to assess the presence of hyperactivity and/or
alterations in exploratory behavior, as have been demonstrated in other rodent
models (Mei et al., 2016, Fish et al., 2016). Postnatal exposure to 4 g/kg ETOH,
regardless of maternal DID, led to hyperactivity in the OF. Similar patterns of
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hyperactivity were found in the EPM, although this effect was only detectable in
offspring with combined maternal DID and postnatal intubations of 4 g/kg ETOH.
These findings are in line with the previous mouse and rat models of FASD showing
hyperactivity in young ETOH-exposed animals (Melcer et al., 1994, Kim et al.,
2013). To better understand these changes, activity in the center zone of the OF and
open arms of the EPM were assessed alongside the number of entries into the center
zone or open arms. For the OF, offspring receiving postnatal intubations of 4 g/kg
traveled further in the center but did not differ in the number of entries into the
center from the controls, suggesting that increased distance traveled observed in
these offspring reflect hyperactivity that is unrelated to center avoidance. In contrast,
ETOH exposure was shown to influence both explorations of the open arms and the
number of entries into open arms, but the effects were different based on dose- and
paradigm of exposure. Distance traveled in the open arms was significantly
increased in both groups receiving combined DID and postnatal intubations,
regardless of postnatal dose (3 or 4 g/kg ETOH). Open arm visits were elevated in
both groups exposed to 4 g/kg ETOH postnatally, but not those exposed to 3 g/kg
ETOH. Therefore, dose-dependent increases in total activity in the EPM appeared to
be due to changes in open arm exploration. Alterations in open arm exploration have
similarly been shown in previous rodent models of FASD with rats (Brocardo et al.,
2012, Osborn et al., 1998).
The present findings from the OF and EPM are interesting and suggest multiple
potential effects of ETOH, including hyperactivity and increases in the choice to
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enter an open arm and/or to travel within the open arms. Postnatal exposure to 4 g/kg
ETOH was generally associated with hyperactivity in the OF, regardless of prenatal
treatment. Postnatal 4 g/kg ETOH also increased visits to the open arms in the EPM.
The combination of maternal DID and postnatal 4 g/kg ETOH mirrored these effects,
while also producing increased open arm distance. It is intriguing that those with 4
g/kg ETOH alone tended to make more entries into open arms, but failed to show
increased distances traveled in the open arms. This suggests that these subjects
exited the open arms having explored the arms less thoroughly than those with
combined maternal and postnatal 4 g/kg ETOH exposure. It may be concluded that
postnatal ETOH exposure at the 4 g/kg dose may reduce the inhibitory control of
entries into an open arm, while the combination of maternal DID and postnatal
ETOH intubation may reduce the inhibitory control of further exploration of the
open arm after an entry. The present phenotypes of hyperactivity and inhibitory
failures are an important feature of the present mouse models, as those with FASD
are typically hyperactive and may have difficulty avoiding risky behaviors or
aversive consequences, leading to various adverse consequences in childhood and
adolescence (Green et al., 2007) into adulthood (Moore & Riley, 2015).
Additional deficits were identified in the Morris Water Maze. Offspring exposed to
neonatal 4 g/kg ETOH, with or without maternal DID, performed as well as controls
on the first trial in the maze, but quickly developed a pattern of longer latencies and
distances traveled to the platform relative to controls. This impairment was observed
across four days of testing and into the probe test, where these offspring failed to
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persistently return to the platform location. These subjects also tended to take longer
to locate the novel platform in the reversal component, although they reached the
novel platform without longer distances traveled. These animals did not appear to
have motor deficits, as they performed as well as controls on the visible platform test.
Taken together, it is concluded that the poorer performance resulted from neonatal
ETOH-induced learning deficits rather than motivational or motor effects. These
effects were not affected by maternal ETOH consumption and were not reliably
produced by neonatal exposure to the lower dose of 3 g/kg ETOH. Offspring with
exposure to 3 g/kg ETOH tended to show longer escape latencies, although this did
not reach significance in combined DID with this treatment and did not result in
increased distances to escape. Taken together, these data suggest that higher neonatal
doses may be necessary to produce spatial learning deficits in these mice, as has been
described in analogous 3rd-trimester rat models (Cronise et al., 2001). Robust learning
deficits suggest face validity for the neonatal exposure model, as poor learning
outcomes are commonly reported among children and adolescents with FASD (Green,
2007).
The data generated in this study display ETOH-induced alterations in at least three
domains: activity regulation, inhibitory control, and spatial learning. These
phenotypes were expressed following neonatal exposure to higher doses of ETOH,
specifically the 4 g/kg dose which resulted in longer exposures to BECs above 200
mg/dl. These findings are in line with the broader literature on critical windows in the
third trimester of brain development. More uniquely though, these data suggest that
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the present 3-trimester model, combining maternal ETOH treatment with postnatal
intubations, can model interactions between ETOH exposures prior to and during the
third-trimester equivalent of brain development. Although with the current paradigm,
maternal DID alone did not alter behavior due likely to a lower BEC, it led to a
qualitatively distinct inhibitory deficit when combined with neonatal treatment. The
present data do not suggest a clear mechanism for such effects but do suggest that
maternal DID and neonatal intubations may be suitable methods for investigating how
early, sub-threshold exposures to ETOH could contribute to FASD. Based on the
present findings, future research should apply the present models to investigate how
early, moderate ETOH exposures may impact inhibitory pathways and/or alter their
sensitivity to later insults.
In summary, the current study examined behavioral characteristics in adolescent
mice with early ETOH exposure. By manipulating the dosage, timing, and methods
of ETOH delivery, our results provided an inclusive aspect on how behavioral
changes induced by fetal alcohol exposure are affected by these factors. It is a useful
reference for the future investigation on the neurogenetic mechanism underlying the
FASD.
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Chapter 4: Summary and Future Direction

Chromium & T cell immunity
Chromium (Cr) is a heavy metal widely used in the various industrial process. Since
the first cancer case associated with chromium was reported in Scotland a century
ago (Langard, 1990), a myriad of studies have been conducted in an attempt to
elucidate the relationship between exposure to chromium compounds and increased
incidence of certain cancers. Given that the immune system defends the host body
against mutated/tumor cells, any factor that affects components of the immune
system may sabotage the host immunity, cause immunosuppression and therefore,
nurture the development of cancer. Due to the natural capacity of T cells in
mediating immune response and in directing cytolysis of the mutated/tumor cells, T
cells play a central role in host anti-tumor immunity.
As the first step to understand the effect of Cr(VI) on the T cells mediated anti-tumor
immunity as well as its role in Cr(VI) carcinogenesis, in current study, we used
primary cultured mouse splenic T cells as an in vitro model and tested whether and
how T cells are affected by Cr(VI) at concentrations relevant to occupational and
environmental exposure. Results obtained in this study provide a reference for the
future in vivo study and lay a groundwork for the further investigation on the
mechanism of the immunosuppression caused by Cr(VI). Our results showed that
Cr(VI) inhibited the activation and function of T cells. The regulation of T cells
activation and response is a complex process consisting of both stimulatory and
inhibitory cell intrinsic signaling pathway, known as immune checkpoints (Sharma
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and Allison, 2015). The inhibition of the stimulatory pathway or the activation of the
inhibitory pathway prevents T cells response against mutated/tumor cells and
contributes to tumorigenesis. The immune checkpoint protein, such as cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) and programmed death-1 (PD-1), can
inhibit the T cell effector function (Rudd et al., 2009, Dong et al., 2017). Therefore,
in order to fully understand the process of how Cr(VI) disrupts T cells immunity and
facilitates the immune escape of mutated/tumor cells, it will be interesting to
investigate the role of Cr(VI) on the immune checkpoint pathways.

Early ethanol exposure & behavioral deficits in young mouse
Behavioral anomalies such as hyperactivity and impulsive behaviors as well as
deficits in learning and memory are observed in children with FASD. Project 2 and 3
characterized behavioral phenotypes resulted from ETOH exposure during the early
neurodevelopmental period in pre-weaning and adolescent mice. Our results showed
that offspring exposed to 4 g/kg ETOH per day from PD 4 to PD 10 (third trimester),
regardless of prenatal treatment (first- and second trimester) displayed a series of
behavioral deficits. The results are in line with previous studies showing that
binge-like alcohol exposure during the early postnatal period in rats and mice causes
deficits in spatial learning and memory (Wozniak et al., 2004, Furumiya and
Hashimoto, 2011).
Given the advantages provided by mouse model in studies on the etiology of a
variety of neurological disorders, as well as results presented in current studies, there
are a number of future investigations needed to be done to explore the neurogenetic
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mechanisms beneath the observed behavioral changes. First of all, it will be
important to evaluate morphological changes in brain structures that correspond to
the behavioral deficits outlined in our results. Structures, such as prefrontal cortex,
hippocampus, amygdala, and thalamus, are of particular interest due to their roles in
cognitive regulation, spatial learning, information retention, and anxiety, fear
conditioning (Pourtois et al., 2013, Duarte-Guterman et al., 2015, Frith and Dolan,
1996). In addition, the decreased number of neurons was observed in rodents
subjected to acute postnatal ETOH treatment (Bonthius and West, 1990, Dikranian et
al., 2005, Wozniak et al., 2004). Although apoptotic neurodegeneration has been
linked to reduced brain volume and neuron losses (Saito et al., 2016, Wozniak et al.,
2004), changes in neurogenesis, especially neurogenesis during the third trimester
are worth investigating. The previous study showed that the suppression of
neurogenesis during the third trimester may lead to abnormal neuro-behavioral
manifestations prevalent in preterm infants (Malik et al., 2013). Therefore, studies on
how early ETOH exposure affects neurogenesis and its potential genetic targets will
serve as a valuable groundwork for developing and screening therapeutic compounds
against FASD. Moreover, accumulating evidence suggests that ethanol-induced
behavior defects, such as hyperactivity, may be associated with hypomyelination
caused by ethanol-induced damage to oligodendrocytes and consequently agenesis
of the corpus callosum (CC). The effects of ethanol on CC development may also
provide valuable information towards better understanding ethanol neurotoxicity.
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